Emerging within the UK, retatrutide, a novel compound , is generating considerable buzz within the scientific community regarding its promise for body regulation. This dual GIP and GLP-1 agent agonist seems to offer a substantial improvement over existing therapies, showing encouraging results in preliminary clinical trials . Researchers believe it